Recurrent ERBB2 alterations are associated with esophageal adenocarcinoma brain metastases.
Lawson NM. et al, (2025)
Open-label, phase Ia study of STING agonist BI 1703880 plus ezabenlimab for patients with advanced solid tumors.
Harrington K. et al, (2025), Future Oncol, 21, 195 - 200
Redefining PD1 as a guardian of stem-like T cells.
Jackson M. and Parkes EE., (2024), Nat Rev Immunol
Validity and timeliness of cancer diagnosis data collected during a prospective cohort study and reported by the English and Welsh cancer registries: a retrospective, comparative analysis.
Jackson A. et al, (2024), Lancet Oncol, 25, 1476 - 1486
A retrospective analysis of the validity and timeliness of cancer diagnosis data collected during a prospective cohort study and reported by the English and Welsh cancer registries
Jackson A. et al, (2024), The Lancet Oncology
Reactivation of low avidity tumor-specific CD8+ T cells associates with immunotherapeutic efficacy of anti-PD-1.
Sugiyarto G. et al, (2023), J Immunother Cancer, 11
cGAS-STING signalling in cancer: striking a balance with chromosomal instability.
Beernaert B. and Parkes EE., (2023), Biochem Soc Trans
Investigating the effects of homologous recombination deficiency on radiotherapy response in pre-clinical prostate cancer
Kwon J. et al, (2023), EUROPEAN UROLOGY, 83
Phase I, first-in-human trial evaluating the STING agonist BI 1387446 alone and in combination with ezabenlimab in solid tumors
Calvo E. et al, (2023), ANNALS OF ONCOLOGY, 34, S626 - S626
A non-coding RNA balancing act: miR-346-induced DNA damage is limited by the long non-coding RNA NORAD in prostate cancer
Fletcher CE. et al, (2022), Molecular Cancer, 21, 82 - 82
When breaks get hot: inflammatory signaling in BRCA1/2-mutant cancers.
van Vugt MATM. and Parkes EE., (2022), Trends Cancer, 8, 174 - 189
Activation of a cGAS-STING-mediated immune response predicts response to neoadjuvant chemotherapy in early breast cancer.
Parkes EE. et al, (2022), Br J Cancer, 126, 247 - 258
The tumor microenvironment and immune responses in prostate cancer patients.
Kwon JTW. et al, (2021), Endocr Relat Cancer, 28, T95 - T107
Phase I, first-in-human trial evaluating BI 1387446 (STING agonist) alone and in combination with ezabenlimab (BI 754091; anti-PD-1) in solid tumors.
Harrington K. et al, (2021), CANCER RESEARCH, 81
The clinical and molecular significance associated with STING signaling in breast cancer.
Parkes EE. et al, (2021), NPJ Breast Cancer, 7
Development of Immunotherapy Combination Strategies in Cancer.
Yap TA. et al, (2021), Cancer Discov, 11, 1368 - 1397
Metastasis and Immune Evasion from Extracellular cGAMP Hydrolysis.
Li J. et al, (2021), Cancer Discov, 11, 1212 - 1227
Circulating biomarkers and outcomes from a randomised phase 2 trial of gemcitabine versus capecitabine-based chemoradiotherapy for pancreatic cancer.
Willenbrock F. et al, (2021), Br J Cancer, 124, 581 - 586